JPWO2019195810A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019195810A5 JPWO2019195810A5 JP2021504139A JP2021504139A JPWO2019195810A5 JP WO2019195810 A5 JPWO2019195810 A5 JP WO2019195810A5 JP 2021504139 A JP2021504139 A JP 2021504139A JP 2021504139 A JP2021504139 A JP 2021504139A JP WO2019195810 A5 JPWO2019195810 A5 JP WO2019195810A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- formula
- halo
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 162
- 150000001875 compounds Chemical class 0.000 claims description 128
- 150000003839 salts Chemical class 0.000 claims description 107
- 125000005843 halogen group Chemical group 0.000 claims description 75
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 45
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- 125000003118 aryl group Chemical group 0.000 claims description 44
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 125000001188 haloalkyl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 3
- -1 2- thiofryl Chemical group 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010050389 Cerebral ataxia Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 102100030013 Endoribonuclease Human genes 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000008999 Giant Cell Carcinoma Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 claims description 2
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 claims description 2
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000000014 lung giant cell carcinoma Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000021090 palsy Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 150000002828 nitro derivatives Chemical class 0.000 claims 4
- 150000003141 primary amines Chemical class 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862654263P | 2018-04-06 | 2018-04-06 | |
| US62/654,263 | 2018-04-06 | ||
| PCT/US2019/026198 WO2019195810A2 (en) | 2018-04-06 | 2019-04-06 | Atf6 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024066563A Division JP2024096924A (ja) | 2018-04-06 | 2024-04-17 | Ａｔｆ６阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521271A JP2021521271A (ja) | 2021-08-26 |
| JPWO2019195810A5 true JPWO2019195810A5 (he) | 2022-04-13 |
| JP7476167B2 JP7476167B2 (ja) | 2024-04-30 |
Family
ID=66248737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504139A Active JP7476167B2 (ja) | 2018-04-06 | 2019-04-06 | Ａｔｆ６阻害剤およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10829485B2 (he) |
| EP (1) | EP3774782A2 (he) |
| JP (1) | JP7476167B2 (he) |
| KR (1) | KR20210028144A (he) |
| CN (1) | CN112313224A (he) |
| AU (1) | AU2019247533B2 (he) |
| BR (1) | BR112020020181A2 (he) |
| CA (1) | CA3096139A1 (he) |
| CL (1) | CL2020002573A1 (he) |
| IL (1) | IL277794B2 (he) |
| MX (2) | MX2020010469A (he) |
| RU (1) | RU2020136310A (he) |
| SG (1) | SG11202009570SA (he) |
| WO (1) | WO2019195810A2 (he) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022004212A (es) * | 2019-10-09 | 2022-06-08 | Praxis Biotech LLC | Moduladores de atf6 y usos de los mismos. |
| EP4041728A1 (en) * | 2019-10-09 | 2022-08-17 | Praxis Biotech LLC | Atf6 modulators and uses thereof |
| EP4001917A1 (en) | 2020-11-12 | 2022-05-25 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Inhibitors for use in treating liver disorders |
| KR102644194B1 (ko) * | 2021-02-22 | 2024-03-08 | 주식회사 이노셀젠헬스케어 | 종양의 진단 및 치료를 위한 표적단백질로서의 atf6 |
| WO2022266232A1 (en) * | 2021-06-16 | 2022-12-22 | Sanford Burnham Prebys Medical Discovery Institute | Methods and compositions for treating chronic liver disease and hepatocellular carcinoma |
| CN113501787A (zh) * | 2021-08-20 | 2021-10-15 | 黑龙江省科学院石油化学研究院 | 一种合成6-三氟甲基-3-甲基吲唑的方法 |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| KR20240030727A (ko) * | 2022-08-31 | 2024-03-07 | 단국대학교 천안캠퍼스 산학협력단 | 퓨릴티아졸계 화합물 및 이를 유효성분으로 포함하는 근감소증 예방 또는 치료용 조성물 |
| WO2024105104A1 (en) | 2022-11-16 | 2024-05-23 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
| WO2024115512A1 (en) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline derivatives |
| WO2024115546A1 (en) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Fungicidal compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE247117T1 (de) * | 1998-04-20 | 2003-08-15 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen |
| EP2385041B1 (en) * | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
| CA2632021A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Gaba-b receptor modulators |
| AR069650A1 (es) * | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| ES2761295T3 (es) * | 2009-03-02 | 2020-05-19 | Stemsynergy Therapeutics Inc | Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula |
| SG10201502073PA (en) * | 2009-12-22 | 2015-05-28 | Vertex Pharma | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| BR112015002938A2 (pt) * | 2012-08-10 | 2017-08-08 | Hoffmann La Roche | compostos de carboxamida pirazol, composições e métodos de uso |
| WO2014055944A1 (en) * | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
| EA039043B1 (ru) * | 2015-04-22 | 2021-11-25 | Райджел Фармасьютикалз, Инк. | Пиразольные соединения и способ получения и применения данных соединений |
| EP3312170A4 (en) * | 2015-06-22 | 2018-12-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-di-substituted imidazole derivative |
| PE20220502A1 (es) * | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | Compuestos utiles como inhibidores de cinasa |
| WO2017146128A1 (ja) * | 2016-02-26 | 2017-08-31 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| US10357477B2 (en) * | 2016-09-13 | 2019-07-23 | Regents Of The University Of Minnesota | Anticancer compounds |
| US9911469B1 (en) * | 2016-11-10 | 2018-03-06 | Micron Technology, Inc. | Apparatuses and methods for power efficient driver circuits |
-
2019
- 2019-04-06 AU AU2019247533A patent/AU2019247533B2/en active Active
- 2019-04-06 EP EP19719005.1A patent/EP3774782A2/en active Pending
- 2019-04-06 WO PCT/US2019/026198 patent/WO2019195810A2/en active Application Filing
- 2019-04-06 SG SG11202009570SA patent/SG11202009570SA/en unknown
- 2019-04-06 RU RU2020136310A patent/RU2020136310A/ru unknown
- 2019-04-06 CA CA3096139A patent/CA3096139A1/en active Pending
- 2019-04-06 US US16/377,156 patent/US10829485B2/en active Active
- 2019-04-06 KR KR1020207031697A patent/KR20210028144A/ko unknown
- 2019-04-06 MX MX2020010469A patent/MX2020010469A/es unknown
- 2019-04-06 IL IL277794A patent/IL277794B2/he unknown
- 2019-04-06 BR BR112020020181-2A patent/BR112020020181A2/pt not_active Application Discontinuation
- 2019-04-06 CN CN201980037115.9A patent/CN112313224A/zh active Pending
- 2019-04-06 JP JP2021504139A patent/JP7476167B2/ja active Active
-
2020
- 2020-08-12 US US16/992,000 patent/US20210221803A1/en not_active Abandoned
- 2020-10-02 MX MX2023010326A patent/MX2023010326A/es unknown
- 2020-10-05 CL CL2020002573A patent/CL2020002573A1/es unknown
-
2023
- 2023-05-26 US US18/324,826 patent/US20240124434A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McLoughlin et al. | Colchicine-binding site inhibitors from chemistry to clinic: a review | |
| IL277794B1 (he) | מעכבי atf6 ושימושים בהם | |
| Guo et al. | Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma | |
| JPWO2019195810A5 (he) | ||
| Fronik et al. | Structure–activity relationships of triple-action platinum (IV) Prodrugs with albumin-binding properties and immunomodulating ligands | |
| Dubey et al. | Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex | |
| JP2006265245A5 (he) | ||
| Ward et al. | Pazopanib in renal cell carcinoma | |
| Zuo et al. | Bifunctional naphtho [2, 3-d][1, 2, 3] triazole-4, 9-dione compounds exhibit antitumor effects in vitro and in vivo by inhibiting dihydroorotate dehydrogenase and inducing reactive oxygen species production | |
| Huang et al. | Bifunctional naphthoquinone aromatic amide-oxime derivatives exert combined immunotherapeutic and antitumor effects through simultaneous targeting of indoleamine-2, 3-dioxygenase and signal transducer and activator of transcription 3 | |
| CN103347520A (zh) | 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂 | |
| Peng et al. | Altered glycolysis results in drug‑resistant in clinical tumor therapy | |
| JP2005524631A5 (he) | ||
| Chomanicova et al. | The Role of AMPK/mTOR Signaling Pathway in Anticancer Activity of Metformin: This paper is dedicated to the 70th anniversary of the founding of Physiologia Bohemoslovaca (currently Physiological Research) | |
| JP6968080B2 (ja) | ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法 | |
| US9387213B2 (en) | Small molecules inhibiting oncoprotein Myc | |
| Dubey et al. | Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression | |
| Ziffels et al. | Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice | |
| JPWO2019031614A5 (he) | ||
| Pourhamzeh et al. | Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma | |
| Tamiya et al. | Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion | |
| Lu et al. | NHC-gold (I)-alkyne complexes induced hepatocellular carcinoma cell death through bioorthogonal activation by palladium complex in living system | |
| Aruchamy et al. | Design, Synthesis, and Anti-Breast Cancer Potential of Imidazole–Pyridine Hybrid Molecules In Vitro and Ehrlich Ascites Carcinoma Growth Inhibitory Activity Assessment In Vivo | |
| Riu et al. | Design, synthesis, and biological screening of a series of 4′-fluoro-benzotriazole-acrylonitrile derivatives as microtubule-destabilising agents (MDAs) | |
| JPWO2020206424A5 (he) |